Hemispherx (HEB) Receives Two New Patents for Alferon(R) LDO
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (Amex: HEB) announced today the granting of two new United States Patents for the use of Alferon® LDO (Low Dose Oral Interferon Alfa-n3).
Alferon® LDO (Human Leukocyte Derived) is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, and, like Alferon N Injection®, should not cause antibody formation, which is a known problem with recombinant interferon. Alferon® LDO is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. Oral interferon could be economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by influenza and other emerging viruses. Oral administration of Alferon® LDO, with its anticipated affordability, low toxicity, expected non-production of antibodies, and broad range of potential bioactivity, could be a breakthrough treatment for prevention for viral diseases including influenza.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Alferon® LDO (Human Leukocyte Derived) is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, and, like Alferon N Injection®, should not cause antibody formation, which is a known problem with recombinant interferon. Alferon® LDO is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. Oral interferon could be economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by influenza and other emerging viruses. Oral administration of Alferon® LDO, with its anticipated affordability, low toxicity, expected non-production of antibodies, and broad range of potential bioactivity, could be a breakthrough treatment for prevention for viral diseases including influenza.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
- A.G. Lafley Returns as President/CEO of Procter & Gamble (PG)
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
